Please assess the completion status of the following clinical trial:

Trial Title: Determining Swallow Outcomes in Head & Neck Lymphedema Subjects Receiving Early Intervention With Pneumatic Compression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years~2. A previous diagnosis of oropharyngeal carcinoma requiring treatment with radiation therapy~3. Diagnosis/evidence of lymphedema stage 1a or higher by clinical presentation based upon MD Anderson Cancer Center Head and Neck Lymphedema rating scale~4. EAT-10 score \>4 at Baseline and Randomization Visits (prior to randomizing subject)~5. The head and neck garments must fit appropriately (for patients with a tracheostomy, the fit will be assessed to ensure that the garments do not interfere with their tracheostomy)~6. Ability to perform swallow exercises~7. Willing and able to comply with the study protocol requirements and all study-related visit requirements~8. Willing and able to provide informed consent prior to study participation~Exclusion Criteria:~1. Synchronous treatment for cancer (may or may not have successfully complete prior cancer treatment)~2. Other known causes of dysphagia such as previous radiation to the head and neck, or neuromuscular or neurodegenerative known to have a strong association with dysphagia (i.e., Parkinsons, ALS, MS, OPMD)~3. Poorly controlled: kidney disease (glomerular filtration rate \< 30 mls per minute), hypoproteinemia, pulmonary hypertension, hypothyroidism or parathyroidism, cyclic edema, or Munchausen Syndrome (for which endocrinologist recommends against neck compression)~4. Carotid sinus hypersensitivity syndrome~5. Symptomatic carotid artery disease, as manifested by a recent transient ischemic attack (within 30 days), ischemic stroke, or amaurosis fugax (monocular visual ischemic symptoms or blindness)~6. Symptomatic bradycardia in the absence of a pacemaker~7. Internal jugular venous thrombosis (within 3 months)~8. Increased intracranial pressure or other contraindications to internal or external jugular venous compression~9. Acute radiation dermatitis, unhealed surgical scar, unhealed or open wounds, surgical flap less than 6-8 weeks post-operative~10. Facial or head and neck dermal metastasis~11. Acute infection/inflammatory disease of the head and neck region (e.g., facial infection, parotid gland abscess, acute cellulitis, or other uncontrolled skin/untreated head and neck inflammatory skin disease)~12. Any condition in which increased venous and lymphatic return is undesirable~13. Heart failure (acute pulmonary edema, decompensated acute heart failure)~14. Subject is pregnant or trying to become pregnant~15. Acute venous disease (acute thrombophlebitis, acute deep venous thrombosis, acute pulmonary embolism)~16. The subject has comorbidities which, in the opinion of the investigator, will not be appropriate for the study or the subject has an estimated life expectancy of less than 1½ months~17. Any subject who is considered to be part of a vulnerable population (e.g., prisoners or those without sufficient mental capacity)~18. The subject has participated in any investigational drug or device research study within 30 days of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FT-CC and Swallow Exercises (Type: EXPERIMENTAL): None
- Swallow Exercises (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues